Analytical Cellular Pathology · 2019 · 11 citations · 31 references
MedicinePathologyUrologyGenitourinary OncologyMolecular OncologyTumor PathologyBiomarkers In Genitourinary CancerBiomarkers In Urologic OncologyBladder CancerCancer BiomarkersImmuno-oncology BiomarkersUrothelial CarcinomaImmunohistochemical BiomarkersImmunohistochemical DetectionImmunohistochemical MarkersImmunohistochemical StainingPrognostic Marker AssessmentPrognostic Marker EvaluationTissue Microarrays
Background . Urothelial carcinoma of the urinary bladder (UCB) is the commonest bladder tumor. Cyclooxygenase-2 (COX-2) mediates angiogenesis, cell survival/proliferation, and apoptosis. This study investigates the relation of COX-2 immunostaining in UCB to clinicopathological parameters in Saudi Arabia. Methods . The study population includes 123 UCB and 25 urothelial mucosae adjacent to UCB. UCB samples were collected before any local or systemic therapy. Tissue microarrays were designed and constructed, and TMA blocks were sliced for further immunohistochemical staining. Immunohistochemical staining was done using a mouse anti-human COX-2 monoclonal antibody. A cutoff point of 10% was chosen as the threshold to determine low and high COX-2 immunostaining. Results . COX-2 immunostaining is higher in UCB than in the adjacent urothelium (<mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" id="M1"><mml:mi>p</mml:mi><mml:mo>=</mml:mo><mml:mn>0.033</mml:mn></mml:math>). High COX-2 immunostaining is associated with high-grade UCB (<mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" id="M2"><mml:mi>p</mml:mi><mml:mo>=</mml:mo><mml:mn>0.013</mml:mn></mml:math>), distant metastasis (<mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" id="M3"><mml:mi>p</mml:mi><mml:mo>=</mml:mo><mml:mn>0.031</mml:mn></mml:math>), lymphovascular invasion (<mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" id="M4"><mml:mi>p</mml:mi><mml:mo>=</mml:mo><mml:mn>0.008</mml:mn></mml:math>), positive muscle invasion (<mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" id="M5"><mml:mi>p</mml:mi><mml:mo>=</mml:mo><mml:mn>0.017</mml:mn></mml:math>), pT2 and above (<mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" id="M6"><mml:mi>p</mml:mi><mml:mo>=</mml:mo><mml:mn>0.003</mml:mn></mml:math>), and high anatomical stages (stage II and above). High COX-2 immunostaining is an independent predictor of higher tumor grade (<mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" id="M7"><mml:mi>p</mml:mi><mml:mo><</mml:mo><mml:mn>0.001</mml:mn></mml:math>), muscle invasion (<mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" id="M8"><mml:mi>p</mml:mi><mml:mo>=</mml:mo><mml:mn>0.015</mml:mn></mml:math>), advanced pathological T (<mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" id="M9"><mml:mi>p</mml:mi><mml:mo>=</mml:mo><mml:mn>0.014</mml:mn></mml:math>), lymphovascular invasion (<mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" id="M10"><mml:mi>p</mml:mi><mml:mo>=</mml:mo><mml:mn>0.011</mml:mn></mml:math>), and distant metastasis (<mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" id="M11"><mml:mi>p</mml:mi><mml:mo>=</mml:mo><mml:mn>0.039</mml:mn></mml:math>). High COX-2 immunostaining is associated with lower overall survival rate (<mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" id="M12"><mml:mi>p</mml:mi><mml:mo>=</mml:mo><mml:mn>0.019</mml:mn></mml:math>). Conclusion . COX-2 immunostaining is associated with the invasiveness of UCB which may be used as an independent prognostic marker. COX-2 may be a significant molecule in the initiation and progression of UCB. Molecular and clinical investigations are required to explore the molecular downstream of COX-2 in UCB and effectiveness of COX-2 inhibitors as adjuvant therapy along with traditional chemotherapy.
31
Ahmedin Jemal, Freddie Bray, Jacques Ferlay et al. · CA A Cancer Journal for Clinicians · 2011 · 55K citations · Full text
Cyclooxygenase Regulates Angiogenesis Induced by Colon Cancer Cells
Masahiko Tsujii, Sunao Kawano, Shingo Tsuji et al. · Cell · 1998 · 2.3K citations · Full text
Medicine, Cancer Biology, Oncology +14